Full-Time

Senior Automation Engineer

Posted on 5/9/2026

Evotec

Evotec

1,001-5,000 employees

Global drug-discovery services via partnerships

Compensation Overview

$125k - $155k/yr

+ Bonus

Seattle, WA, USA + 1 more

More locations: Redmond, WA, USA

In Person

Category
Process Engineering
Required Skills
Python
SQL
Data Governance
Data Analysis
Requirements
  • Bachelor’s or Master’s degree in Science or Engineering and 5 or more years of relevant experience; or Associate’s degree in science-related area and 8 or more years of relevant experience; or High school diploma or GED and 10 or more years of relevant experience.
  • Robust background in control system automation, including design, installation, programming, and validation of automated processes.
  • Strong expertise in AVEVA PI system architecture, configuration, and development (PI AF, PI Vision, integrations).
  • Experience integrating AVEVA PI with process control systems such as DeltaV (preferred), SCADA, or DCS platforms.
  • Knowledge of FDA CFR 21 Part 11 compliance requirements.
  • Proven track record of completing projects successfully using strong engineering and project management expertise.
  • Experience supporting or defining automation standards, governance, and change management in a global manufacturing environment.
  • Familiarity with software development lifecycle (SDLC) practices for automation systems.
  • Demonstrated proficiency in OT system architecture and industrial data infrastructure.
  • Prior experience with computer software validation.
  • Involvement in global teams or Centers of Excellence.
  • Experience applying GAMP5 risk-based methodologies for validated process automation system changes.
  • Participation in regulatory inspections or audit support.
  • Familiarity with single-use technologies and systems.
  • Experience with automation platforms such as DeltaV, Siemens, Allen-Bradley, or Wonderware.
  • Certification in AVEVA PI System administration or development.
  • Knowledge of additional OT or IT systems used in industrial environments (e.g., SCADA, DCS, MES).
  • Understanding of cybersecurity principles in OT environments.
  • Proficiency in scripting or programming languages (e.g., Python, SQL) to enhance PI system capabilities.
Responsibilities
  • Oversee the comprehensive deployment of the AVEVA PI system, encompassing planning, configuration, validation, and rollout across international sites.
  • Architect, standardize, and sustain the PI system framework, utilizing PI AF and PI Vision to meet process control, data management, and visualization requirements.
  • Lead the continuous development of the AVEVA PI ecosystem by integrating new data sources, use cases, and business-driven enhancements, including advanced analytics and reporting.
  • Define and implement integration strategies between AVEVA PI and process control systems (e.g., DeltaV, SCADA, DCS), enabling real-time data access and operational insights.
  • Support governance and lifecycle management of automation platforms, including maintaining alignment of global standards and change management practices across sites.
  • Participate in defining and improving global software development lifecycle (SDLC) processes for automation and data systems.
  • Collaborate with global MSAT and site automation teams to ensure alignment with manufacturing platform objectives and automation strategies.
  • Ensure seamless OT infrastructure integration, maintaining secure and reliable connectivity between PI systems and process control environments.
  • Implement and uphold data governance and management standards to ensure data integrity, consistency, and accessibility.
  • Develop reporting, visualization, and analytics tools using AVEVA PI to deliver actionable insights to stakeholders.
  • Participate in the design and implementation of process control strategies, including batch tracking, process limits, and data-driven or predictive control approaches.
  • Provide technical guidance and support to global teams, resolving issues and ensuring system reliability and performance.
  • Collaborate with cross-functional groups, including IT, OT, and engineering, to align PI and automation systems with company objectives.
  • Develop and improve technical documentation including specifications, SOPs, and training materials.
  • Author and execute validation protocols (IQ/OQ/PQ) and test scripts for automation and data systems.
  • Lead or support technical root cause analyses, incident investigations, and troubleshooting of process control and data integration issues.
  • Manage CAPAs and change controls, collaborating with the site Manufacturing Technical Services (MTS) team to implement updates.
  • Serve as a key member of the New Product Introduction (NPI) team, ensuring automation, PI data integration, and MES readiness for new processes.
  • Provide technical oversight or support for projects involving third-party system integrators or vendors.
  • Offer technical support to manufacturing sites as needed, focusing on process control, automation systems, and data infrastructure.
  • Stay informed on advancements in AVEVA PI, process control technologies, and OT systems to propose innovative solutions.
  • Partner with diverse teams, including manufacturing, process engineering, data scientists, utility operations, maintenance, quality assurance, and validation, to drive operational enhancements.
Desired Qualifications
  • Certification in AVEVA PI System administration or development.
  • Knowledge of additional OT or IT systems used in industrial environments (e.g., SCADA, DCS, MES).
  • Understanding of cybersecurity principles in OT environments.
  • Proficiency in scripting or programming languages (e.g., Python, SQL) to enhance PI system capabilities.
  • Participation in regulatory inspections or audit support.
  • Familiarity with single-use technologies and systems.
  • Experience with automation platforms such as DeltaV, Siemens, Allen-Bradley, or Wonderware.
  • Knowledge of FDA CFR 21 Part 11 compliance requirements.

Evotec provides R&D services for drug discovery and development through strategic partnerships with pharma, biotech, and academic institutions, using platforms like iPSCs and machine learning. It conducts experiments and data analysis with iPSC-derived cellular models and AI/ML tools to identify and optimize drug candidates, often incorporating patient-derived materials for precision medicine, offering end-to-end discovery through clinical development under contract. The company differentiates itself with an integrated, data-driven, cell-based platform within a collaboration model and a focus on precision medicine, biologics, and gene therapy, with a strong US and European presence. Its goal is to bring new and better medicines to patients faster and at lower cost by making drug discovery and development more efficient through partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hamburg, Germany

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Just-Evotec Biologics revenue surged 104% in Q4 2025 with $650M Sandoz deal.
  • Horizon plan delivers €75M savings by 2027 via site optimization to 10 hubs.
  • New leaders like CFO Hinshelwood and CCO Khan drive commercial execution and partnerships.

What critics are saying

  • Horizon's 800 job cuts erode iPSC expertise, prompting Bristol Myers Squibb to switch providers.
  • Charles River Laboratories captures discovery clients amid Evotec's restructuring disruptions.
  • Schrödinger steals AI deals through faster in-silico cycles exploiting Evotec's negative EBITDA.

What makes Evotec unique

  • Proprietary platforms like PanOmics and iPSC-based modeling enable precision drug discovery.
  • Just-Evotec Biologics redefines affordable biologics manufacturing for partners.
  • AI-driven innovation integrates with wet-lab infrastructure across small molecules and cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Evotec who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 8th, 2026
Evotec delivers $67M cost savings and $650M Sandoz deal amid 1.1% revenue decline

Evotec SE reported mixed Q4 2025 results, with group revenue increasing 14.5% to €253.3 million, though full-year revenue fell 1.1% to €788.4 million. Adjusted group EBITDA for Q4 rose 103.6% to €58 million, whilst full-year EBITDA increased 81.9% to €41.1 million. The Just-Evotec Biologics segment achieved breakthrough growth, with Q4 revenue surging 104.2% and full-year revenue rising 39.8% to €259.4 million. The company secured a $650 million agreement with Sandoz and received multiple milestone payments from partnerships. Evotec delivered over €60 million in annualised cost savings and reduced capital expenditure by approximately 60%. The company is implementing its Horizon transformation programme, expected to deliver €75 million in structural savings by end-2027, though this involves closing four sites and eliminating 800 positions.

The Associated Press
Apr 7th, 2026
Evotec nominates Dieter Weinand as supervisory board chairman to drive commercial execution

Evotec has nominated Dieter Weinand as chairman of its supervisory board, pending approval at the 11 June 2026 annual general meeting. Weinand will succeed Prof. Dr Iris Löw-Friedrich, whose term concludes at the meeting as part of the company's planned succession process. Weinand brings over 30 years of pharmaceutical industry experience, having served as president, CEO and chairman of Bayer Pharmaceuticals and held senior roles at Pfizer, Bristol Myers Squibb and Sanofi. He currently serves on several biotech boards and will reduce his board commitments to comply with German corporate governance requirements. The appointment aims to strengthen Evotec's commercial execution, strategic partnerships and profitability as the Hamburg-based life sciences company continues its transformation. Weinand holds an MS in pharmacology and toxicology from Long Island University.

The Associated Press
Apr 1st, 2026
Evotec appoints Dr. Ashiq H. Khan as chief commercial officer with $7B+ deal track record

Evotec has appointed Dr Ashiq H Khan as chief commercial officer. Dr Khan brings over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, having closed more than $7 billion in agreements across US, EU and APAC markets. In his new role, Dr Khan will build a globally integrated commercial organisation aligned with Evotec's scientific capabilities. He most recently served as chief business officer at Iktos and previously held leadership roles at Proteros and Schrödinger. Evotec is a life science company specialising in drug discovery and development, integrating AI-driven innovation with advanced technologies. The company employs over 4,800 experts across Europe and the US.

The Associated Press
Mar 19th, 2026
Evotec receives $10M milestone from Bristol Myers Squibb for kidney cancer drug trial

Evotec has received a $10 million milestone payment from Bristol Myers Squibb following the initiation of a Phase 1 clinical study for BMS-986506, a protein degradation treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer. The study marks the first clinical milestone in the strategic protein degradation partnership between Evotec and Bristol Myers Squibb, which began in 2018 and was expanded in 2022. BMS-986506 is a cereblon E3 ligase modulator, or "molecular glue", developed using Evotec's multi-omics screening platform and AI-supported data analytics. The collaboration combines Evotec's PanOmics and PanHunter platforms with Bristol Myers Squibb's library of CELMoD agents to discover novel molecular glue degraders for oncology and other therapeutic areas.

Yahoo Finance
Mar 16th, 2026
Evotec unveils "Horizon" plan with $85M savings, 800 job cuts and 10-site footprint by 2028

Evotec has unveiled "Horizon", a transformation plan targeting €75 million in savings and guiding 2026 EBITDA to €0–40 million. The plan focuses on operational excellence, scientific leadership and commercial execution, building on earlier restructuring that delivered over €60 million in savings through end-2025. The company will reduce its global footprint from 14 sites to 10 over two years, resulting in approximately 800 position reductions. Evotec emphasises owned technology hubs in Toulouse and Verona as integrated discovery and preclinical development centres. Chief executive Christian Wojczewski said Evotec has upgraded commercial leadership and business development, with prospects increasing during the second half of 2025. The company previously streamlined its asset pipeline by 30% and reduced capital expenditure by 60% whilst strengthening its balance sheet.